Vascular Endothelial Growth Factor A-A (VEGFAA) Antibody (Biotin)
169€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Name
Vascular Endothelial Growth Factor A-A (VEGFAA) Antibody (Biotin)
Category
Primary Antibodies
Provider
Abbexa
Reference
abx320020
Tested Applications
ELISA
Description
VEGFAA Antibody (Biotin) is a Rabbit Polyclonal against VEGFAA conjugated to Biotin.
Documentos del producto
Instrucciones
Data sheet
Especificaciones del producto
| Category | Primary Antibodies |
| Immunogen Target | Target: Vascular Endothelial Growth Factor A-A (VEGFAA) Immunogen: Recombinant Zebrafish Vascular endothelial growth factor A-A protein (24-188AA). |
| Host | Rabbit |
| Reactivity | Zebrafish |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Biotin |
| Isotype | IgG |
| Purity | > 95% |
| Purification | Purified by Protein G. |
| Size 1 | 20 µg |
| Size 2 | 50 µg |
| Size 3 | 100 µg |
| Size 4 | 200 µg |
| Size 5 | 1 mg |
| Form | Liquid |
| Tested Applications | ELISA |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | O73682 |
| Gene ID | 30682 |
| NCBI Accession | NP_001103819.2, NM_001110349.2, NP_571483.1, NM_131408.3 |
| Alias | L-VEGF,MVCD1,VEGF,VPF,Vascular permeability factor |
| Background | Antibody anti-VEGFA |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Background
VEGFA is a key member of the vascular endothelial growth factor (VEGF) family and plays a crucial role in angiogenesis, vascular permeability, and endothelial cell proliferation VEGFA binds primarily to its receptors VEGFR-1 and VEGFR-2, triggering signaling pathways like PI3K/AKT and ERK/MAPK to promote blood vessel formation during embryonic development, wound healing, and tissue repair Dysregulated VEGFA expression is associated with pathological angiogenesis observed in cancer, diabetic retinopathy, and age-related macular degeneration (AMD) VEGFA also increases vascular permeability by altering endothelial junctions, contributing to fluid leakage in conditions such as inflammation and tumors Targeted therapies, such as bevacizumab and other anti-VEGF agents, inhibit VEGFA activity to suppress angiogenesis and tumor growth in various cancers and ocular diseases